Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

Publication

Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

Journal Paper/Review - Jun 15, 2016

Reichegger Hermann, Jochum Wolfram, Förbs Diana, Hader Claudia, Früh Martin

Citation

Reichegger H, Jochum W, Förbs D, Hader C, Früh M. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. Oncol Res Treat 2016; 39:461-3.

Type

Journal Paper/Review (English)

Journal

Oncol Res Treat 2016; 39

Publication Date

Jun 15, 2016

Issn Electronic

2296-5262

Pages

461-3

Brief description/objective

BACKGROUND
Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

CASE REPORT
Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma.

CONCLUSION
These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed.